trial

The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset

NCTId NCT06128408
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 300 (estimated)
Sponsored by Peking University
Primary completion 2024-10-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
300 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2023-12-01
Primary completion
2024-10-12
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Peking UniversityLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
300
Phase
NA
Primary Completion Date
2024-10-12
Status
UNKNOWN
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Peking University
company
indication
Schizophrenia, Treatment-Resistant
indication
Treatment-resistant Schizophrenia
indication